Abstract: A contrast-amplifying carrier for observing a sample, includes a transparent substrate bearing at least one absorbent coating suitable for behaving as an antireflection coating when it is illuminated at normal incidence at an illumination wavelength ? through the substrate and when the face of the coating opposite the substrate is in contact with a medium referred to as a transparent ambient medium, the refractive index n3 of which is lower than that of the refractive index n0 of the substrate. The absorbent coating comprises: an absorbent sublayer referred to as the contrast sublayer, deposited on the surface of the transparent substrate; and an absorbent layer referred to as the sensitive layer, distinct from the contrast sublayer and comprising between 1 and 5 sheets of a graphene-type material. Methods for producing and for using such a contrast-amplifying carrier are also provided.

Abstract: The present invention relates to the Compound of following formula (I): or a pharmaceutically acceptable salt thereof. The present invention also relates to a pharmaceutical composition containing such a compound and a method for preparing such a compound.

Abstract: A method for preparing a nanoporous silica sol-gel matrix containing at least one amine reactant selected from hydroxylamine, methylhydroxylamine, tertbutylhydroxylamine, methoxyamine, tetraethylenepentamine, dicarboxylic acid dihydrazides, particularly adipic acid dihydrazide, and the salts thereof, said method including the following steps: a) synthesising a gel from tetramethoxysilane or from a mixture of tetramethoxysilane and another organosilicon precursor selected from among phenyltrimethoxysilane, phenyltriethoxysilane, a fluoroalkyltrimethoxysilane, a fluoroalkyltriethoxysilane, a chloroalkylmethoxysilane, a chloroalkylethoxysilane, an alkyltrimethoxysilane, an alkyltriethoxysilane, an aminopropyltriethoxysilane and the mixtures thereof, the synthesis being performed in an aqueous medium at a temperature ranging from 10 to 70° C.

Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of diseases mediated by the NRP-1/OBR complex signaling pathway. In particular, the present invention relates to a method for treating a disease selected from the group consisting of cancers, obesity and obesity related diseases, anorexia, autoimmune diseases and infectious diseases in a subject in need thereof comprising administering the subject with a therapeutically effective amount of an antagonist of the NRP-1/OBR signaling pathway.

Abstract: The present invention relates to an engineered immune cell defective for Suv39h1. Preferably, said engineered immune cell further comprises a genetically engineered antigen receptor that specifically binds a target antigen. The present invention also relates to a method for obtaining a genetically engineered immune cell comprising a step consisting in inhibiting the expression and/or activity of Suv39h1 in the immune cell; and further optionally comprising a step consisting in introducing in the said immune cell a genetically engineered antigen receptor that specifically binds to a target antigen. The invention also encompasses said engineered immune cell for their use in adoptive therapy, notably for the treatment of cancer.

Abstract: The present invention relates to regulatory T cell and uses thereof. By their immunosuppressive and anti-inflammatory activities, regulatory T cells play a central role in peripheral tolerance and thus critically prevent the development of autoimmune and inflammatory disorders. The inventors showed that Foxp3+CD4+ Tregs express high levels of LT?, which negatively regulates their immunosuppressive signature. They demonstrated that the adoptive transfer of LT??/? Tregs in mice protects from dextran sodium sulfate (DSS)-induced colitis and attenuates inflammatory bowel disease (IBD), multi-organ autoimmunity and the development of CAC. The inventors also showed that by mixed bone marrow chimeras that LT? expression specifically in hematopoietic cells negatively controls the immunosuppressive signature of Tregs. In particular, the present invention relates to regulatory T cell characterized in that it does not express or expresses reduced levels of lymphotoxin alpha.

Abstract: The present invention concerns a solid nanocomposite material consisting of a polymer-matrix in which are dispersed alkali metal, hydronium or ammonium salts of polyanionic components, wherein the polymer-matrix comprises at least a linear or branched polymer or copolymer containing one or several poly(ethylene oxide) (PEO) chains, said polymer or copolymer being optionally crosslinked and each PEO chain having at least 4 ethylene oxide monomer units. The present invention relates also to a photonic, e.g. optoelectronic, device comprising such a nanocomposite material. Such material and device can be used as phosphorescence emitter, for crop growth lighting or for generating singlet oxygen.

Abstract: The present invention relates to methods and devices to consolidate memory and/or cognitive functions by monitoring brain rhythms and delivering a stimulus at an appropriate stage of sleep cycle.

Abstract: An electronic device for measuring a speed of flow of a fluid that includes at least two electroacoustic transducers adapted for emitting and/or receiving acoustic signals through the flow of the fluid, the electronic device being adapted for determining a measurement of the speed of flow of the fluid from the characteristics of an acoustic signal emitted and one or more acoustic signals received, these received acoustic signals corresponding to reflections of the emitted acoustic signal.

Abstract: The present invention relates to a compound of the following formula (I). The invention also relates to uses thereof as a chromophore as such or for building pigments displaying special optical effects, including metal-like reflection.

Abstract: A method for determining wavefront shapes of N angular channels CL of different propagation directions PL, said propagation directions PL being determined by a mean propagation direction vector , from a single signal image acquisition I(x,y) of a multi-angular signal light beam containing said angular channels, each angular channel Ci being separated from other angular channels Cj by an angular separation ??ij defined by ??ij=arccos, where “·” stands for the inner product between and .

Abstract: The invention relates to a method for generating a unique identifier of a subject from a genotyped DNA sample from said subject, the method comprising the steps of: obtaining a number N?2 of genomic positions of interest, said obtained genomic positions being such that, in a population of M subjects, these genomic positions exhibit a polymorphism of at least one nucleotide having an allelic frequency of between 25% and 35%, for the minority allele; combining in pairs the obtained genomic positions by means of logical functions so as to obtain a binary code bc.

Abstract: The invention relates to a process for preparing methyl mercaptan from a mixture of carbon oxide, hydrogen sulfide and hydrogen, in the presence of a catalyst based on molybdenum and potassium supported on zirconia, said catalyst not comprising any promoter.

Abstract: The present invention relates to pseudotyped retrovirus-like particles or retroviral vectors comprising both engineered envelope glycoproteins derived from a virus of the Paramyxoviridae family fused to a cell targeting domain and fused to a functional domain. The present invention also relates to the use of said pseudotyped retrovirus-like particles or retroviral vectors to selectively modulate the activity of specific subsets of cells, in particular of specific immune cells. These pseudotyped retrovirus-like particles or retroviral vectors are particularly useful for gene therapy, immune therapy and/or vaccination.

Abstract: A medical analysis device with cellular impedance signal processing comprises a memory (4) arranged to receive pulse data sets, each pulse data set comprising impedance value data that are associated each time with a time marker, these data together representing a curve of cellular impedance values that are measured as a cell passes through a polarised opening. This device further comprises a classifier (6) comprising a convolutional neural network receiving the pulse data sets as input and is provided with at least one convolutional layer, which convolutional layer has a depth greater than or equal to 3, and at least two fully connected layers, in addition to an output layer rendering a cell classification from which a pulse data set is derived.

Abstract: Probes for the detection of ?-lactamase-type enzymatic activity. In particular, novel fluorogenic substrates for detecting the presence of a catalytically active ?-lactamase and a detection method using such substrates.

Abstract: The present application relates to a double-stranded DNA molecule comprising a first double-stranded DNA molecule (1) connected to a second double-stranded DNA molecule (2) by at least one covalent bond which is not a phosphodiester, phosphorothioate, phosphoramidate or phosphorodiamidate bond, preferably by a tether, said tether preferably being a double-stranded DNA molecule.

Abstract: Sarcomas are rare malignant tumors arising from the mesenchymal tissues at all body sites. The inventors show that in a mouse model of p16/p19 deficiency prone to tumor development, the absence of the mouse pantetheinase Vnn1 enhances the frequency of aggressive fibrosarcomas. They also show that reintroduction of a catalytically active form of the Vnn1 pantetheinase limits tumor growth in vivo. Interestingly, VNN1 expression in human sarcomas is associated with reduced aggressiveness and lower risk of metastatic relapse in patients. In conclusion, Vnn1 represents a novel marker of sarcoma and may modulate tumor aggressiveness by sustaining myofibroblast cell differentiation, thereby limiting evolution towards undifferentiated tumors. The present invention relates to the use of Vnn1 as a biomarker and a therapeutic target in sarcomas.

Abstract: The invention relates to a system (10) adapted to measure multiple biophysical characteristics of cells, the system (10) comprising: a microfluidic chip (12) provided with a microfluidic channel (14) which allows cells to flow through, the microfluidic channel (14) having an inlet (14a), an outlet (14b), and a lateral opening (14c) situated between the inlet (14a) and the outlet (14b); and a capacitive sensor (30) integrated in the microfluidic chip, adapted to obtain biophysical characteristics of a single cell in the microfluidic channel (14) by directly manipulating the single cell by sensor elements (31, 32) through the lateral opening (14c) of the microfluidic channel (14), the sensor (30) comprising a stationary part and an electrostatically driven movable part which is movable relative to the stationary part, the stationary part being fixed to the microfluidic chip (12), the movable part being arranged in the lateral opening (14c) of the microfluidic channel (14), wherein a portion of the sensor elemen

Abstract: The present invention relates to a novel use of total cellular iron, preferably under the form of ferrous iron (Fe2+), as a marker of cancer stem cells (CSCs). The invention also relates to methods using said iron marker, in particular for metastatic cancer diagnosis or treatment, for screening for compounds of interest, as well as for killing CSCs.